Solis Partners Installs Solar Power at Bristol-Myers Squibb
MANASQUAN, N.J. (February 6, 2014)-- Solis Partners, a leading commercial solar energy provider, has completed the installation of a roof-mounted solar photovoltaic system for Bristol-Myers Squibb (NYSE: BMY), a premier biopharmaceutical company based in New York City that discovers, develops and delivers innovative medicines for treating serious diseases and is a recognized leader in environmental stewardship.
The 777.14-kilowatt system consists of 3,172 panels that span the entirety of the 106,500-square-foot parking structure at the company’s campus in Hopewell Township, New Jersey.
“It was really rewarding to partner with Bristol-Myers Squibb on this solar installation that will be owned and operated under a full service Power Purchase Agreement,” said Jamie Hahn, co-founder and managing director of Solis Partners. “Reducing the company’s environmental footprint with onsite solar power generation provides a cost-effective path to sustainability. Bristol-Myers is once again demonstrating their commitment to environmental leadership.”
In the first year of operation, the system is expected to produce approximately 965,000 kilowatt-hours of clean energy to the Bristol-Myers Squibb campus. Over the life of the system, this will equate to the reduction of more than 9,800 metric tons of CO2 gas emissions - roughly equivalent to the impact of removing 2,050 cars from the roads.
About Solis Partners
Solis Partners is a leading developer and integrator of solar power systems for commercial, industrial and utility clients. Solis designs, finances and constructs distributed solar energy generation assets enabling customers to meet their long-term energy needs while reducing operating costs and addressing their carbon liabilities. For more information, please call 732-722-5917 or visit www.solispartners.com.